Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Bioequivalence of Generic Imiquimod Cream, 5% When Compared to Aldara™ (Imiquimod) Cream, 5% in the Treatment of Actinic Keratosis

ClinicalTrials.gov ID: NCT00948428

Public ClinicalTrials.gov record NCT00948428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 1:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Double-Blind, Randomized, Parallel Group, Vehicle-Controlled Study to Determine the Clinical Equivalence of a Generic Imiquimod Cream, 5% and Aldara™ Cream in Subjects With Actinic Keratosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

At the end of the study, safety and efficacy outcome measures will be compared to determine a) if dosing with Generic Imiquimod cream, 5% is therapeutically equivalent to the currently marketed Aldara (imiquimod) cream, 5% and b) if both imiquimod 5% creams are superior in comparison to the Vehicle cream.

Study identification

NCT ID
NCT00948428
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Actavis Inc.
Industry
Enrollment
462 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2008
Primary completion
Feb 28, 2009
Completion
Mar 31, 2009
Last update posted
Sep 3, 2020

2008 – 2009

United States locations

U.S. sites
20
U.S. states
15
U.S. cities
20
Facility City State ZIP Site status
Burke Pharmaceutical Research Hot Springs Arkansas 71913
Associates in Research, Inc. Fresno California 93720
Skin Surgery Medical Group, Inc. San Diego California 92117
Cherry Creek Research, Inc. Denver Colorado 80209
FXM Research Corp. Miami Florida 33175
MedaPhase, Inc. Newnan Georgia 30263
Deaconess Clinic, Inc. Evansville Indiana 47713
Minnesota Clinical Study Center Fridley Minnesota 55432
Mt. Sinai School of Medicine New York New York 10029
Derm Research Center of New York, Inc. Stony Brook New York 11790
University Dermatology Consultants, Inc. Cincinnati Ohio 45219
Oregon Medical Research Center, P.C. Portland Oregon 97223
Rhode Island Hospital, Dermatopharmacology Division Providence Rhode Island 02903
Dermatology Associates of Knoxville, P.C. Knoxville Tennessee 37917
Tennessee Clinical Research Center Nashville Tennessee 37215
DermResearch, Inc. Austin Texas 78759
Suzanne Bruce & Associates, P.A. Houston Texas 77056
Dermatology Clinical Research Center of San Antonio San Antonio Texas 78229
Dermatology Research Center, Inc. Salt Lake City Utah 84124
Premier Clinical Research Spokane Washington 99204

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00948428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 3, 2020 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00948428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →